"FDA Approves Groundbreaking Gene Therapies for Sickle Cell Anemia, Paving the Way for a Cure"
TL;DR Summary
The FDA has approved the first gene therapies, Casgevy and Lyfgenia, for sickle cell anemia. Casgevy, which utilizes the CRISPR gene editing tool, will cost $2.2 million, while Lyfgenia will cost $3.1 million. These treatments offer potential cures for the disease by modifying and transplanting blood stem cells. However, the high cost raises concerns about accessibility for patients, despite the potential benefits.
- First FDA approved gene therapies for sickle cell anemia cost millions Business Insider
- Why the FDA’s approval of revolutionary sickle cell gene therapy is a ‘big deal’ PBS NewsHour
- A Sickle Cell Breakthrough Is Here. Now the Hard Part. Bloomberg
- New treatments an 'amazing' step in curing sickle cell disease Atlanta News First
Reading Insights
Total Reads
0
Unique Readers
25
Time Saved
2 min
vs 3 min read
Condensed
85%
427 → 62 words
Want the full story? Read the original article
Read on Business Insider